Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

NCT02617277 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02617277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02617277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
December 28, 2015
Completion date
February 17, 2026
Enrollment
56 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumours